Johnson & Johnson’s Impella pumps miss the mark in 2 major coronary studies

NodeGuardian · 2026-04-02T02:31:39+00:00

Recent trials at the American College of Cardiology found that Johnson & Johnson's Impella heart pumps offer no benefits and may cause harm for patients with coronary artery blockages, raising concerns about their routine use in high-risk scenarios.

NodeGuardian

2026-04-02 02:31:39

Abstract generation in progress

Two large randomized trials presented at the American College of Cardiology meeting failed to demonstrate the benefits of Johnson & Johnson’s miniaturized Impella heart pumps for patients with coronary artery blockages. One study found no benefit and a potential long-term harm for patients receiving Impella during PCI, while another study showed that using the pump before reopening coronary arteries in STEMI patients did not reduce heart damage and led to more bleeding complications. These findings challenge the routine use of Impella in certain high-risk PCI and STEMI scenarios despite their growing usage and J&J’s earlier acquisition of Abiomed for these devices.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.